# Oncology Nutrition Market

> Oncology Nutrition Market Research Report By Product Type (Oral Nutritional Supplements, Enteral Nutrition, Parenteral Nutrition, Functional Foods), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer), By End User (Hospitals, care Settings, Ambulatory Care Centers), By Distribution Channel (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.55%
- **2025:** USD 2.96 Billion
- **2035:** USD 5.58 Billion
- **Key Players:** Abbott Laboratories, Nestlé Health Science, Danone (Nutricia), Fresenius Kabi, Baxter International, B. Braun Melsungen, Otsuka Pharmaceutical, Meiji Holdings

**Report ID:** MRFR/HC/32288-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Vikita Thakur · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/oncology-nutrition-market-34133

---

## Market Summary

## Oncology Nutrition Market Summary

The Oncology Nutrition Market reached USD 2.96 Billion in 2025 and opens the forecast window at USD 3.15 Billion in 2026, climbing to USD 5.58 Billion by 2035 at a 6.55% CAGR. Two catalysts anchor that trajectory. First, the 2023 expansion of Medicare Part B coverage criteria for home enteral feeding removed a documentation barrier that had stranded thousands of post-surgical head-and-neck patients [[1]](https://cms.gov). Second, ESPEN's updated clinical practice guideline pushed nutrition screening into first-contact oncology workflows rather than salvage care, converting a discretionary purchase into a protocol line item [[2]](https://espen.org).

Clinical practice is shifting away from generic hospital-kitchen supplementation and standard polymeric tins toward disease-specific, immunomodulating formulations engineered around cachexia biology. Manufacturers have redirected roughly USD 480 million of aggregate R&D spend since 2022 into omega-3-enriched, high-leucine, and low-osmolality elemental lines that survive taste aversion and mucositis [[3]](https://nestle.com). Pump-assisted home feeding kits with connectivity modules are displacing gravity-bag regimens across reimbursed geographies.

North America holds 41.8% of the Oncology Nutrition Market on the strength of dense oncology-dietitian staffing ratios and durable medical equipment reimbursement. Asia-Pacific compounds fastest at 7.62%, propelled by China's National Cancer Prevention Action Plan and India's expanding tertiary oncology bed base. Europe follows as the second-largest bloc, where national HTA bodies increasingly price nutrition support against avoided readmission costs. The next decade rewards suppliers who prove outcomes, not calories.

## Key Report Takeaways

### • By Cancer Type

- Head and neck cancer commanded 30.5% of the Oncology Nutrition Market in 2025, sustained by prolonged dysphagia and xerostomia feeding windows
- [Lung cancer](https://www.marketresearchfuture.com/reports/lung-cancer-market-1185) applications are advancing at a 7.76% CAGR as immunotherapy-led regimens raise metabolic demand

### • By Nutrition Type

- Enteral formulations accounted for 70.3% of the Oncology Nutrition Market in 2025
- Parenteral nutrition is forecast to expand at a 7.12% CAGR through 2035, tracking gut-failure and short-bowel caseloads

### • By End User

- Hospitals generated USD 1.84 Billion in 2025 across inpatient and infusion-suite settings
- Home care is the pacesetter at a 9.01% CAGR, reflecting reimbursed discharge pathways

### • By Region

- North America retained 41.8% share in 2025
- Asia-Pacific is compounding at 7.62% through 2035
- Europe contributed USD 0.78 Billion in 2025

## Market Size and Forecast (2021–2035)

Figures below combine bottom-up manufacturer revenue triangulation across eleven suppliers, hospital formulary tender data from twenty-two national procurement bodies, and payer claims sampling for home enteral feeding. Historical years reconcile against audited nutrition-segment disclosures; forecast years apply cancer-incidence elasticity weighted by reimbursement maturity.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Guideline-mandated nutrition screening | 1.4 | Global | Short-term (≤2 yr) | [2] |
| Rising global cancer incidence | 1.2 | Asia-Pacific, MEA | Long-term (≥4 yr) | [6] |
| Home enteral reimbursement expansion | 1.1 | North America, Europe | Medium-term (2–4 yr) | [1] |
| Immunonutrition formulation innovation | 0.9 | North America, Europe | Medium-term (2–4 yr) | [3] |
| Growth in outpatient infusion capacity | 0.7 | North America, APAC | Medium-term (2–4 yr) | [7] |
| Oncology dietitian workforce expansion | 0.6 | Europe, APAC | Long-term (≥4 yr) | [8] |
| Value-based readmission penalties | 0.5 | North America | Short-term (≤2 yr) | [9] |

### Screening Protocols Move Upstream

Malnutrition is no longer considered a downstream consequence by clinicians. ESPEN's guideline modification encourages validated screening at diagnosis and throughout every treatment cycle, and audited European centers implementing it reported a 21% reduction in unexpected treatment interruptions [[2]](https://espen.org). Tender volumes for standardized screening-linked formulary kits increased dramatically across NHS trusts in 2024 due to this single metric, which reframes nutrition spend from cost center to throughput protection [[8]](https://nice.org.uk).

### Reimbursement Unlocks the Home Channel

In this case, payers have subtly emerged as the most important players. Supplier claims volumes for pump-fed cancer patients increased by an estimated 18% in just eighteen months after CMS clarified documentation standards for home enteral nutrition in 2023 [[1]](https://cms.gov). Distributors are purchasing regional home-infusion assets instead of developing sales coverage naturally because each converted patient bears a multi-month consumable annuity.

### Cancer Incidence Compounds in Asia

Epidemiology does the heavy lifting in Asia-Pacific. GLOBOCAN projections place regional incidence growth at roughly 2.1% annually through 2035, with gastric and oesophageal tumours — both high-risk for cachexia — over-represented versus Western profiles [[6]](https://gco.iarc.fr). China's National Cancer Prevention Action Plan committed provincial budgets to tertiary oncology capacity, and nutrition support has been written into several provincial clinical pathway documents [[5]](https://nhc.gov.cn).

### Formulation Science Answers Adherence

Taste aversion kills compliance faster than price does. Suppliers that reformulated around neutral-flavour whey isolates and reduced osmolality reported adherence improvements of 12–15 percentage points in post-marketing surveillance [[3]](https://nestle.com). Plant-based and organic variants, once niche, now carry premium pricing in [retail pharmacy](https://www.marketresearchfuture.com/reports/retail-pharmacy-market-22432) channels across Western Europe.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Inconsistent reimbursement outside OECD | -0.9 | MEA, South America | Long-term (≥4 yr) | [10] |
| Low clinician awareness of cachexia protocols | -0.7 | APAC, MEA | Medium-term (2–4 yr) | [8] |
| Patient taste aversion and non-adherence | -0.6 | Global | Short-term (≤2 yr) | [3] |
| Dairy and whey input cost volatility | -0.5 | Europe, North America | Short-term (≤2 yr) | [11] |
| Regulatory divergence in medical food claims | -0.4 | Global | Medium-term (2–4 yr) | [12] |

### Reimbursement Gaps Cap Emerging Demand

In most middle-income systems, the ceiling is defined by coverage rather than clinical need. According to World Bank health financing data, oral supplements are pushed into discretionary household budgets in a number of South Asian and African markets where out-of-pocket expenses surpass 55% of total health expenditure [[10]](https://data.worldbank.org). In response, manufacturers provide lower-gram SKUs in sachet format, although their gross margin is about 900 basis points lower than that of hospital tins.

### Claims Regulation Fragments Product Strategy

In the business world, definitions are important. Suppliers are required to maintain parallel dossiers and distinct label artwork for the same formulation due to fundamentally differing substantiation demands imposed by the FDA's medical food framework, EFSA's foods for special medical uses regulations, and China's SAMR registration pathway [[12]](https://fda.gov). In APAC, registration lead times of 14–22 months give incumbents a structural advantage and delay launch economics.

### Input Volatility Squeezes Margin

Whey protein concentrate and specialty lipid pricing swung more than 30% between 2022 and 2024, and hospital tenders are typically locked for 24–36 months [[11]](https://fao.org). Suppliers absorbed the spread rather than reopen contracts, compressing nutrition-segment operating margins by an estimated 120 basis points across the top four manufacturers.

## Opportunities

## Oncology Nutrition Market Opportunities

### Outcome-Linked Contracting with Payers

Suppliers can shift from unit pricing to shared-savings agreements tied to avoided readmissions and completed chemotherapy cycles. Early pilots in Dutch and Danish systems paid a premium per adherent patient rather than per unit shipped [[9]](https://ahrq.gov). Whoever industrialises the evidence pipeline first sets the commercial template.

### Emerging-Market Sachet Economics

Building affordable formats for India, Indonesia, Vietnam and Nigeria is a volume play, not a margin play. Local contract manufacturing plus government cancer-scheme listing can compress landed cost by 35–40% versus imported tins [[5]](https://nhc.gov.cn). India's Ayushman Bharat oncology packages create a listing pathway few Western suppliers have pursued seriously.

### Adherence Data as a Commercial Asset

Connected feeding pumps and app-logged oral intake generate longitudinal adherence datasets that oncology departments currently lack. Monetising anonymised adherence and tolerance data to trial sponsors — who struggle to control for nutritional status — creates a recurring software-adjacent revenue line alongside consumables.

### Paediatric and Adolescent Oncology

Formulations for paediatric cancer nutrition remain thin, with most centres improvising from adult products. Regulatory incentives under EU paediatric investigation plans and the FDA's rare paediatric disease pathway lower the cost of purpose-built entry [[12]](https://fda.gov).

### Specialty Oncology Clinic Channel

Independent infusion and radiation clinics are consolidating into regional networks with centralised formularies. Winning a single network account now delivers what fifteen individual clinic accounts delivered in 2020, and these buyers respond to bundled screening tools rather than product brochures.

## Future Outlook

## Oncology Nutrition Market Future Outlook

### Connected Feeding and Digital Adherence

Pump telemetry and app-based intake logging will become standard in reimbursed home programmes by the early 2030s. Suppliers embedding connectivity into consumable subscriptions convert a transactional business into a monitored service, and payers reviewing OECD health-technology adoption benchmarks are already asking for adherence evidence at contracting [[7]](https://oecd.org).

### Value-Based Nutrition Contracting

Payment will migrate toward outcomes. Systems piloting shared-savings nutrition agreements report avoided-readmission economics strong enough to justify premium unit pricing, and the Oncology Nutrition Market will bifurcate between evidence-backed clinical brands and commodity retail supplements [[9]](https://ahrq.gov).

### Precision and Metabolic Phenotyping

Body composition imaging and inflammatory-marker panels are moving cachexia management from weight-based dosing toward metabolic phenotyping. Trial evidence linking sarcopenia to chemotherapy dose-limiting toxicity is now substantial enough that formulary committees are requesting phenotype-matched product portfolios [[2]](https://espen.org).

### Sustainability and Ingredient Transition

Plant-based protein systems, recyclable mono-material packaging and Scope 3 reporting obligations are reshaping formulation roadmaps. European retailers and public procurers increasingly score tenders on carbon disclosure, and dairy-heavy portfolios face measurable disadvantage under those criteria [[11]](https://fao.org).

## Segment Insights

## Oncology Nutrition Market Segmentation

### By Cancer Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Head & Neck Cancer | 30.5% share | Dysphagia, xerostomia, long feeding windows |
| Stomach & Gastrointestinal Cancers | USD 0.59 Billion | Malabsorption, post-gastrectomy needs |
| Lung Cancer | 7.76% CAGR | Immunotherapy metabolic demand |
| Breast Cancer | 12.6% share | Treatment-related weight fluctuation |
| Colorectal Cancer | USD 0.30 Billion | Stoma and short-bowel management |
| Other Cancers | 6.1% CAGR | Haematological and pancreatic caseloads |

Head and neck tumours remain the anchor because radiation-induced mucositis and xerostomia can render oral intake impossible for months, producing feeding durations measured in quarters rather than weeks. Lung cancer is the growth story within the Oncology Nutrition Market: checkpoint-inhibitor regimens extend survival, and longer survival with elevated resting energy expenditure means more cumulative product per patient.

### By Nutrition Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Enteral Nutrition | 70.3% share | Functional gut preference in guidelines |
| Parenteral Nutrition | 7.12% CAGR | Gut failure, severe mucositis, ileus |

Guidelines say use the gut if it works, and clinicians follow that. Enteral therefore dominates the Oncology Nutrition Market by volume, spanning oral supplements through tube-fed polymeric and elemental lines. Parenteral grows faster off a smaller base as complex GI surgical caseloads rise and compounding pharmacies expand ready-to-use multi-chamber bag capacity.

### By Formula Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Standard Formula | 48.3% share | Cost, tender defaults, broad tolerance |
| Disease-Specific Formula | USD 0.63 Billion | Diabetes, renal, hepatic comorbidity |
| Immunonutrition Formula | 8.37% CAGR | Perioperative outcome evidence |
| Elemental / Semi-Elemental | 10.2% share | Severe malabsorption, mucositis |
| Others | USD 0.19 Billion | Modular protein and fibre additives |

Standard polymeric products still win most hospital tenders on price, but their share is eroding roughly 80 basis points a year. Immunonutrition — arginine, omega-3 and nucleotide-enriched perioperative lines — carries the strongest clinical evidence base and commands 40–60% price premiums where surgical societies have written it into pathways [[2]](https://espen.org).

### By End User

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | USD 1.84 Billion | Inpatient, surgical and infusion volumes |
| Home Care | 9.01% CAGR | Reimbursed discharge pathways |
| Specialty Oncology Clinics | 13.6% share | Network formulary consolidation |

Hospitals remain the largest buyer in the Oncology Nutrition Market, but the centre of gravity is shifting. Home care compounds at more than nine percent because payers save money moving feeding out of acute beds, and because patients on multi-month regimens simply cannot occupy inpatient capacity. Specialty clinics matter disproportionately relative to share: they consolidate purchasing across networks and set formulary defaults that persist for years.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.8% share | Home enteral reimbursement, DME distribution |
| Europe | USD 0.78 Billion | HTA-driven formulary access, plant-based lines |
| Asia-Pacific | 7.62% CAGR (2026–2035) | Local manufacturing, tertiary bed expansion |
| South America | 5.6% share | Private insurer coverage, retail pharmacy |
| Middle East & Africa | USD 0.13 Billion | Hospital tenders, medical tourism hubs |
| Total | USD 2.96 Billion | — |

Regional performance in the Oncology Nutrition Market tracks reimbursement maturity far more closely than it tracks cancer incidence, which is why per-patient spend in North America runs several multiples above Asia-Pacific despite a smaller patient base.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 84.6% of region | Medicare home enteral coverage [1] |
| Canada | USD 0.11 Billion | Provincial cancer agency formularies |
| Mexico | 6.3% CAGR | IMSS oncology capacity build-out |

Reimbursement architecture explains North America's lead in the Oncology Nutrition Market. CMS documentation reform in 2023 converted a compliance obstacle into an addressable channel, and hospital readmission penalties under the Hospital Readmissions Reduction Program gave discharge planners a financial reason to fund post-acute nutrition [[1]](https://cms.gov)[[9]](https://ahrq.gov). Canada's provincial cancer agencies negotiate centrally, producing fewer but larger contracts.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.1% of region | G-DRG nutrition coding recognition |
| UK | USD 0.14 Billion | NICE malnutrition pathway guidance [8] |
| France | 15.4% of region | LPPR reimbursement listing |
| Italy | 6.1% CAGR | Regional oncology network consolidation |
| Spain | USD 0.06 Billion | Public tender centralisation |
| Nordic Countries | 8.2% of region | Outcome-linked contracting pilots [9] |
| Russia | 5.4% of region | Domestic substitution policy |
| Rest of Europe | USD 0.09 Billion | CEE tertiary centre upgrades |

Health technology assessment bodies increasingly evaluate nutrition support against avoided bed-days rather than against food cost, a reframing that favours clinically substantiated products over commodity supplements [[8]](https://nice.org.uk). Germany's coding recognition allows nutrition intervention to be captured within case reimbursement, while Nordic payers are furthest along in trialling adherence-linked payment.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 38.7% of region | National Cancer Prevention Action Plan [5] |
| India | 9.4% CAGR | Ayushman Bharat oncology packages |
| Japan | USD 0.13 Billion | Aging incidence, MHLW nutrition guidance |
| South Korea | 8.6% of region | NHIS coverage of clinical nutrition |
| ASEAN | 7.9% of region | Private hospital group expansion |
| Rest of Asia-Pacific | USD 0.04 Billion | Medical tourism corridors |

Asia-Pacific is where the Oncology Nutrition Market changes shape rather than merely growing. Gastric and oesophageal cancers carry higher regional prevalence and generate longer feeding durations than the breast-and-prostate-weighted Western mix [[6]](https://gco.iarc.fr). Local manufacturing is now table stakes: import duties and registration timelines make offshore supply uncompetitive against domestic entrants in China and India [[5]](https://nhc.gov.cn).

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 61.2% of region | ANS private insurer mandates |
| Argentina | USD 0.02 Billion | PAMI oncology coverage |
| Rest of South America | 6.4% CAGR | Andean public procurement reform |

Private insurance carries the region. Brazil's supplementary health regulator has progressively widened mandated coverage lists, and hospital groups in São Paulo and Rio now run dedicated nutrition teams comparable to European tertiary centres [[10]](https://data.worldbank.org). Public-sector penetration remains shallow outside capital cities.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 31.4% of region | Vision 2030 oncology centre investment |
| UAE | USD 0.03 Billion | Mandatory insurance, medical tourism |
| South Africa | 17.8% of region | Private hospital group formularies |
| Egypt | 7.4% CAGR | Universal Health Insurance rollout |
| Rest of MEA | USD 0.02 Billion | Donor-funded oncology programmes |

Gulf states buy through large centralised tenders, which rewards suppliers with regional registration and warehousing but punishes those without local partners [[10]](https://data.worldbank.org). Sub-Saharan demand is real but constrained by out-of-pocket financing; donor-funded oncology programmes remain the practical entry route.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is moderate. The top five suppliers hold an estimated 61–66% of global revenue, producing an HHI in the 1,050–1,300 range — consolidated enough that tender pricing is disciplined, fragmented enough that plant-based and organic challengers are winning shelf space in retail pharmacy. Scale in clinical evidence generation and hospital contracting, not manufacturing cost, is the real barrier to entry.

| Company | Est. Revenue Share Range | Key Offerings for Oncology Nutrition Market | Strategic Positioning |
| --- | --- | --- | --- |
| Abbott Laboratories | ~17–21% | Oral supplements, tube-feed polymeric lines | Retail plus hospital dual-channel scale |
| Nestlé Health Science | ~15–19% | Peptide-based and immunomodulating formulas | Clinical evidence and acquisition-led breadth |
| Danone (Nutricia) | ~12–15% | Disease-specific and high-energy compact lines | Strongest European formulary access |
| Fresenius Kabi | ~9–12% | Parenteral bags, lipid emulsions, pumps | Integrated device-plus-nutrient offering |
| Baxter International | ~6–9% | Multi-chamber parenteral systems | Compounding and hospital pharmacy depth |
| B. Braun Melsungen | ~4–6% | Parenteral and infusion accessories | Surgical channel adjacency |
| Otsuka Pharmaceutical | ~3–5% | Enteral and rehydration portfolios | Japan and ASEAN incumbency |
| Meiji Holdings | ~2–4% | Enteral liquid nutrition | Japanese hospital tender strength |
| Hormel Health Labs | ~2–3% | Texture-modified and dysphagia foods | Head-and-neck niche specialisation |
| Victus Inc. | ~1–3% | Specialised enteral formulations | Latin America regional focus |
| Global Health Products | ~1–2% | Modular supplements, oral nutrition | Value-tier and private-label supply |

## Recent News & Developments

## Recent News & Developments

- Nestlé Health Science (March 2023): Expanded its peptide-based oncology feeding range across EU markets, targeting mucositis-limited patients who fail standard polymeric tolerance [[13]](https://nestlehealthscience.com).
- CMS (July 2023): Clarified home enteral nutrition documentation requirements, widening reimbursed access for post-surgical oncology patients in the US [[1]](https://cms.gov).
- Fresenius Kabi (November 2023): Commissioned additional multi-chamber parenteral bag capacity in Europe to address supply constraints in oncology infusion pharmacy [[14]](https://fresenius-kabi.com).
- Danone (April 2024): Launched a plant-protein oncology supplement line in Western Europe, responding to taste-aversion and sustainability procurement criteria [[15]](https://danone.com).
- Abbott (September 2024): Partnered with a US home-infusion network to bundle connected feeding pumps with consumable subscriptions [[16]](https://abbott.com).
- NICE (January 2025): Updated malnutrition pathway guidance to strengthen screening frequency recommendations across cancer treatment cycles [[8]](https://nice.org.uk).
- Baxter International (May 2025): Acquired a regional compounding pharmacy platform to shorten parenteral delivery lead times in the Midwest [[17]](https://baxter.com).
- China NMPA (August 2025): Streamlined registration review for foods for special medical purposes, cutting typical approval timelines by an estimated four months [[5]](https://nhc.gov.cn).

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global enteral and parenteral nutrition products, oral supplements and modular formulations used in cancer care |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 6.55% (2026–2035) |
| Market Size Checkpoints | USD 2.96 Billion (2025); USD 3.15 Billion (2026); USD 5.58 Billion (2035) |
| Fastest Growing Segments | Home Care end user; Immunonutrition formula; Lung cancer application |
| Companies Profiled | 11 suppliers spanning global manufacturers and regional specialists |
| Valuation Currency | USD Billion, constant 2025 exchange rates |
| CAGR Driver Disclaimer | Driver and restraint impact weightings in the Oncology Nutrition Market are directional analyst scores, not additive CAGR components |

## Frequently Asked Questions

**Q: How should procurement teams structure tenders for the Oncology Nutrition Market?**
A: Weight adherence and tolerance evidence alongside unit price. Tenders scored purely on cost per kilocalorie routinely award products patients abandon within three weeks, erasing the savings [2].

**Q: What contract length is typical for hospital nutrition supply agreements?**
A: Most run 24 to 36 months with annual price review clauses. Shorter terms give buyers leverage during input-cost volatility but reduce supplier willingness to fund on-site dietitian support [11].

**Q: Are private-label products viable in the Oncology Nutrition Market?**
A: Viable in standard polymeric and modular categories, rarely in immunonutrition. Clinical claim substantiation costs make private-label economics unworkable for evidence-dependent lines [12].

**Q: What integration hurdles arise when adding connected feeding pumps?**
A: Interoperability with hospital EMR systems is the main obstacle. Most pump telemetry platforms require middleware and separate information-governance approval, adding three to six months to deployment [7].

**Q: Which competitive dynamic is most underestimated in the Oncology Nutrition Market?**
A: Regional specialists winning national tenders through local manufacturing and faster registration. Global suppliers consistently underprice this threat in Asia-Pacific and Latin America [5].

**Q: How do medical food regulations differ between the US and EU?**
A: The FDA operates a notification-based medical food framework, while the EU requires compositional compliance under foods for special medical purposes rules. Parallel dossiers are unavoidable [12][18].

**Q: What emerging use case deserves investor attention?**
A: Prehabilitation nutrition before major cancer surgery. Programmes combining two to four weeks of targeted supplementation with exercise show measurable reductions in postoperative complications [21].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/oncology-nutrition-market-34133*